Clinical trial
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk…
NCT00037037 · Herbert Irving Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00037037 |
|---|---|
| Title | Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma |
| Official title | A Phase I Study of Peptide Based Vaccine Therapy in Patients With High-Risk or Metastatic Melanoma |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine, sargramostim, tyrosinase peptide |
| Start date | Oct 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: